BioVie's Bezisterim: A New Approach to Treating Parkinson's Disease by Targeting Inflammation and Insulin Resistance.

BioVie is advancing a new approach to Parkinson's treatment, targeting inflammation and insulin resistance in the brain rather than just dopamine loss. Its lead drug candidate, bezisterim (NE3107), addresses both issues. The company believes insulin resistance drives neurodegeneration and neuronal dysfunction, impairing glucose metabolism, dopamine production, and alpha-synuclein buildup. BioVie's approach reframes the disease at a cellular level, suggesting dopamine loss is a downstream effect rather than the root cause.